<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Tipranavir: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int1055-tipranavir.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int1055-tipranavir.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int1055-tipranavir.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int391-antivirals.htm">Antivirals</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int1088-adefovir.htm" title="Previous: Adefovir">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1005-atazanavir.htm" title="Next: Atazanavir">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Tipranavir</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Tipranavir</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int907-abacavir.htm">Abacavir</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>abacavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>tipranavir</span> <span>reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span> <span>tipranavir</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td><p><span>caution with </span> <span>tipranavir</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td><p><span>plasma concentration of </span> <span>tipranavir</span> <span>increased by</span> <span>atazanavir</span> <span>(also plasma concentration of <span>atazanavir</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>increases plasma concentration of</span> <span>atorvastatin</span> <span>(increased risk of myopathy—reduce dose of <span>atorvastatin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td><p><span>manufacturer of </span> <span>tipranavir</span> <span>advises avoid concomitant use with</span> <span>bosentan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int87-buprenorphine.htm">Buprenorphine</a></td><td><p><span>plasma concentration of </span> <span>tipranavir</span> <span>possibly reduced by</span> <span>buprenorphine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>tipranavir</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>increases plasma concentration of</span> <span>clarithromycin</span> <span>(reduce dose of <span>clarithromycin</span> in renal impairment), also plasma concentration of <span>tipranavir</span> increased by <span>clarithromycin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span> <span>tipranavir</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int397-didanosine.htm">Didanosine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>didanosine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids in tablet formulation may affect absorption of other drugs</p></div></td></tr><tr><td><a href="bnf_int914-esomeprazole.htm">Esomeprazole</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>esomeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1135-etravirine.htm">Etravirine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>etravirine</span> <span>, also plasma concentration of <span>tipranavir</span> increased (avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span>plasma concentration of </span> <span>tipranavir</span> <span>increased by</span> <span>fluconazole</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>fosamprenavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>lopinavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td class="cAI"><p><span>manufacturer of </span> <span>tipranavir</span> <span>advises avoid concomitant use with</span> <span>metoprolol</span> <span>for heart failure</span>  </p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>omeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>possibly increases plasma concentration of</span> <span>quetiapine</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>possibly increases plasma concentration of</span> <span>quinine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span> <span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(reduce dose of <span>rifabutin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>tipranavir</span> <span>possibly reduced by</span> <span>rifampicin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span> <span>tipranavir</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int974-rosuvastatin.htm">Rosuvastatin</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>possibly increases plasma concentration of</span> <span>rosuvastatin</span> <span>—manufacturer of <span>rosuvastatin</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int727-salmeterol.htm">Salmeterol</a></td><td><p><span>manufacturer of </span> <span>tipranavir</span> <span>advises avoid concomitant use with</span> <span>salmeterol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>possibly increases plasma concentration of</span> <span>simvastatin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>tipranavir</span> <span>possibly reduced by</span> <span>St John's wort</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>avoidance of concomitant </span> <span>tipranavir</span> <span>in severe renal and hepatic impairment advised by manufacturer of</span> <span>telithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td><p><span>manufacturer of </span> <span>tipranavir</span> <span>advises caution with</span> <span>vardenafil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1134-vitamin-e.htm">Vitamin E</a></td><td><p><span>increased risk of bleeding when </span> <span>tipranavir</span> <span>given with high doses of</span> <span>vitamin E</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td class="cAI"><p><span></span> <span>tipranavir</span> <span>reduces plasma concentration of</span> <span>zidovudine</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Tipranavir</strong> belongs to <strong>Antivirals</strong> but <strong>Antivirals</strong> has no interactions information.</p></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int1088-adefovir.htm">Previous: Adefovir</a> | <a class="top" href="bnf_int1055-tipranavir.htm#">Top</a> | <a accesskey="]" href="bnf_int1005-atazanavir.htm">Next: Atazanavir</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>